Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.64)
# 199
Out of 5,157 analysts
126
Total ratings
56.9%
Success rate
29.8%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Maintains: Buy | $8 → $5 | $1.45 | +244.83% | 8 | Mar 2, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $5 → $4 | $0.34 | +1,075.78% | 9 | Feb 26, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $5.99 | +200.50% | 2 | Feb 20, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $25.34 | +73.64% | 6 | Feb 10, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 | $24.54 | +54.85% | 9 | Feb 10, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.40 | +328.57% | 4 | Feb 6, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $27.97 | +100.21% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $11.15 | +133.29% | 11 | Oct 31, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $69.88 | +25.93% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $7.72 | +55.44% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $1.31 | +1,121.37% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $12.02 | +365.89% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.01 | +59.68% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.94 | +102.43% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $26.96 | +18.72% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $8.54 | +321.55% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $524.33 | -94.66% | 1 | Aug 22, 2023 |
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $8 → $5
Current: $1.45
Upside: +244.83%
FibroBiologics
Feb 26, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $0.34
Upside: +1,075.78%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $5.99
Upside: +200.50%
Zenas BioPharma
Feb 10, 2026
Reiterates: Buy
Price Target: $44
Current: $25.34
Upside: +73.64%
Kodiak Sciences
Feb 10, 2026
Reiterates: Buy
Price Target: $38
Current: $24.54
Upside: +54.85%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.40
Upside: +328.57%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $27.97
Upside: +100.21%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.15
Upside: +133.29%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $69.88
Upside: +25.93%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $7.72
Upside: +55.44%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $1.31
Upside: +1,121.37%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $12.02
Upside: +365.89%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $5.01
Upside: +59.68%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.94
Upside: +102.43%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $26.96
Upside: +18.72%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $8.54
Upside: +321.55%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $524.33
Upside: -94.66%